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ABSTRACT 
Objective: The objective of the current study is to enhance the solubility of Eprosartan mesylate a BCS Class II drug by employing the 
nanoprecipitation technique. 
Methods: Polymeric nanoparticles of Eprosartan mesylate were prepared by precipitation technique with various polymers like PVP K30, HPMC 
K15M, and Eudragit L100 in various ratios. The incompatibility issues which may arise between the drug and polymers were tested by differential 
scanning calorimetry (DSC). The formed nanosuspensions were evaluated for various parameters like particle size, zeta potential, drug content, and 
dissolution testing. 
Results: Among all the nanosuspension formulations, E12 formulation prepared with Eudragit L 100 showed better evaluation characteristics. SEM 
and DSC analysis showed no major interactions with the excipients. The maximum drug release was showed at 12h. The formulation E12 showed 
the particle size of 81.5±5.5 nm and zeta potential of-55.1mv.  
Conclusion: The nano-precipitation method improved the dissolution as well as the bioavailability of Eprosartan mesylate nanosuspension. 
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INTRODUCTION 
Administration of medicine through oral route is the most preferred 
method as it is best, convenient owing to its ease of administration, 
less pronounced adverse effects, easy intake, and patient compliable. 
In recent years significant effort has been focused on the 
improvement of new drug delivery systems [1]. Among the newer 
drug substances, nearly 40% of them are hydrophobic. The 
preparation and formulation of nanosuspension, which shows a 
substantial increment in solubility and permeability, is the best 
approach to increase bioavailability. Pharmaceutical nano-
suspension is defined as submicron colloidal dispersions of nano-
sized drug particles stabilized by surfactants, which consist of the 
hydrophobic drug without any matrix material [2-7]. In the 
nanoprecipitation method, simply a drug is dissolved in a suitable 
solvent and then the drug solution is mixed with anti-solvent (in 
which drug is insoluble) in the presence of surfactant. Rapid 
addition of drug solution to such anti-solvent (generally water) leads 
to rapid supersaturation of drug in the solution, and formation of 
ultrafine amorphous nano-sized or crystalline drug [8]. 
Nanoprecipitation method gives many advantages like a simple 
process, low energy consumption, low cost of equipment, ease of 
scale-up, and offers stable products. Eprosartan mesylate is a BCS 
class II drug which has low solubility but high permeability [9-11]. 
Various studies on Eprosartan have shown an improvement in 
solubility and dissolution by the preparation of nanosuspensions 
[12, 13], SMEDDS [14, 15], and solid dispersions [16]. To avoid the 
toxicity of organic solvents, PEG is preferred as a diffusive phase. 
The aim of the present study is to formulate and evaluate 
nanosuspension of Eprosartan mesylate by nanoprecipitation 
method using PVP K30, HPMC K15 M, and Eudragit L 100. 
MATERIALS AND METHODS 
Materials 
Eprosartan mesylate is obtained as a gift sample from J. B. Chemical 
and Pharmaceuticals Ltd, Mumbai, PVP K30, HPMC K15 M were 
procured from Loba chem. Pvt Ltd, Mumbai, Eudragit L 100 is a gift 
sample from Evonik Industries, Mumbai, Poloxamer 188 is procured 
from BASF, Mumbai, and all other ingredients used in the 
preparation were of analytical grade. 
Methods 
Formulation of eprosartan mesylate nanosuspension 
Polymeric nanoparticles have been prepared by employing the 
nanoprecipitation technique [10]. A predetermined quantity of 
polymers as mentioned in table 1 are dissolved in 15 ml of PEG 200 
with the help of a vortex mixer for 5 min duration to form into a 
diffusion phase. To the above-formed diffusion phase, accurately 
weighed 200 mg of the drug is added and see that the drug was 
completely dissolved in it. The aqueous phase is prepared by 
dissolving Poloxomer 188 (0.5% solution) in water, which is a non-
solvent. The diffusive (PEG) phase is slowly transferred into the 
aqueous phase (35 ml) under stirring at 1000 RPM. After continuous 
stirring for abour30 min of stirring the mixture is homogenized under 
a high-speed homogenizer for 30 min at 7000 RPM. The resultant 
suspension is preserved and used as such for further study. 
Evaluation of eprosartan nanosuspension 
Particle size analysis 
Total formulations of the drug were exposed to Scanning Electron 
Microscopy (SEM) for particle size determination and particle size 
had been determined and recorded [17]. 
Zeta potential 
Zeta potential is a measure of the charge on the electrical double 
layer of the nanoparticle, which indicates the various stability 
concerns. Zeta potential measurements have been conducted at a 
temperature of 25 °C along with an electric field strength of 23 V/m, 
using Zetasizer (Malvern). 
Percentage Entrapment efficiency 
The % entrapment is determined by taking around 2 ml formulation 
into Nessler’s cylinder tube (10 ml) and centrifuged at 2000-3000 
RPM for 4 h. The supernatant layer formed after centrifugation is 
filtered using Whatman filter paper (No: 41) and diluted using 
Phosphate buffer (6.8 pH) up to 10 ml and the resultant solution for 
drug content was analyzed at specific lambda max of the drug 
utilizing UV visible spectrophotometer (Systronics 2202) for already 
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developed method. These tests were replicated 3 times and the 
result was recorded. % EE was calculated using the below formula % EE =  
Total drug content − Free drug
Total drug used
 X 100 
 
Table 1: Formulation of eprosartan mesylate nanosuspension 
Formulation code Eprosartan mesylate 
(mg) 
Polymer (%) Stabilizer (%) 
poloxamer 188 PVP K 30 HPMC K 15 M EUDRAGIT L 100 
E1 200 0.5 -- -- 0.5 
E2 200 1.0 -- -- 0.5 
E3 200 1.5 -- -- 0.5 
E4 200 2.0 -- -- 0.5 
E5 200 -- 0.5 -- 0.5 
E6 200 -- 1.0 -- 0.5 
E7 200 -- 1.5 -- 0.5 
E8 200 -- 2.0 -- 0.5 
E9 200 -- -- 0.5 0.5 
E10 200 -- -- 1.0 0.5 
E11 200 -- -- 1.5 0.5 
E12 200 -- -- 2.0 0.5 
 
In vitro dissolution studies 
Drug release from the nanosuspension formulations was studied 
using an 8 station dissolution test apparatus (Electro lab TDT 08L) 
employing a USP II type paddle stirrer at a speed of 50 rpm and 
37±1 °c. The dissolution medium consisted of a phosphate buffer of 
pH 6.8 (900 ml). The drug release from various nanosuspension 
formulations at pre-specified time intervals was measured from the 
developed and validated method by UV visible spectrophotometer 
(Systronics 2202). The dissolution experiments were conducted in 
triplicate. The dissolution data were fitted into various release 
kinetics like zero order, first order, Higuchi, and Peppas models to 
describe various release patterns [18, 19]. 
Attenuated total reflectance studies 
The pure Eprosartan mesylate powder was taken and the ATR 
spectrum was recorded in Bruker instrument, which was compared 
to that of reference, and the ATR spectrum of final formulation was 
recorded priory to identify the compatibility issues between the API 
and selected excipients. 
Differential scanning calorimetry 
DSC scan of the pure drug was conducted using an automatic 
thermal analyzer system, accurately weighed about 5 mg of 
Eprosartan Mesylate was transferred and the scans were recorded. 
The entire samples were run at a scanning rate of 10˚C/min from 25-
250˚C. The DSC was conducted for final formulation also to identify 
the compatibility issues [20]. 
RESULTS AND DISCUSSION 
Particle size 
All the formulations prepared were in the nanoparticles range and 
the best formulation i.e. E12 showed particle size of 81-95 nm were 
shown in table 2 and fig. 1, the satisfactory zeta potential of 55.1±1 
mv (fig. 2) and percentage drug entrapped was 94.51. 
 
Table 2: Evaluation parameters for eprosartan nanosuspension 
Formulation Particle size (nm) Zeta Potential (mv)# % Drug entrapped 
E1 321-347 10.4±1 88.51 
E2 331-321 12.2±2 85.41 
E3 391-314 12.2±2 86.42 
E4 265-284 10.5±3 87.28 
E5 158-178 41.2±1 81.24 
E6 167-148 41.2±3 83.66 
E7 191-205 43.2±2 81.24 
E8 101-124 41.2±2 82.57 
E9 100-128 45.2±1 92.64 
E10 121-134 42.2±1 90.24 
E11 98-104 52.4±3 93.47 
E12 81-95 55.1±1 94.51 
# mean±SD, n=3 
 
 
Fig. 1: SEM image of eprosartan mesylate nanosuspension (E12) 
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Fig. 2: Zeta potential graph of eprosartan mesylate nanosuspension (E12) 
 
In vitro dissolution studies 
The drug release from various formulations was shown in fig. 3, 4, 5 
and the drug release characteristics are shown in table 3. The drug 
release profiles showed different values; the formulations prepared 
with varied concentrations Eudragit L 100 i.e. E9, E10, E11 and E12 
showed percent drug release of 100.01±2.04, 99.21±2.73, 
98.41±2.04, 99.53±1.98 at the end of 7th, 8th, 10th and 12th hour 
respectively. Based on the above release pattern the E12 the 
formulation prepared with 2 % of Eudragit L 100 showed a release 
pattern according to the prescribed limits. 
The entire dissolution data is fitted into various kinetic models to 
describe the release mechanisms. The zero-order kinetic model 
shows the correlation coefficient r2 values in the range of 0.9336 to 
0.9856, indicating the drug release mechanism followed zero-order 
kinetics. The first order r2 lies in the range of 0.7703 to 0.9405 
indicating that the drug release followed zero-order kinetics. The r2 
values of the Higuchi model range from 0.9494 to 0.9941, indicating 
the drug release mechanism is diffusion. The n value of Peppas 
kinetics showed the majority lies in the range of 0.5–1 indicating 
nonfickian form of diffusion. Based on the above all parameters the 
E12 was selected as the best formulation and proceeded for further 
studies. 
The Nanoprecipitation method was successfully employed and a 
stabilized nanosuspension was formed by using the polymers were 
reported in various studies [11]. 
 
 
Fig. 3: Drug release plot of eprosartan mesylate from formulations prepared with PVP K30 (mean±SD; n=6) 
 
 
Fig. 4: Drug release plot of eprosartan mesylate from formulations prepared with HPMC K 15 M (mean±SD; n=6) 
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Fig. 5: Drug release plot of eprosartan mesylate from formulations prepared with Eudragit L 100 (mean±SD; n=6) 
 
Table 3: Release characteristics of eprosartan nanosuspension formulations 
Formulation code Correlation coefficient values (R2) Diffusion exponent (n) value of peppas 
Zero-order First-order Higuchi’s model Peppas model 
E1 0.9363 0.9168 0.9707 0.9230 0.48 
E2 0.9702 0.7850 0.9494 0.9200 0.58 
E3 0.9766 0.8893 0.9639 0.9548 0.58 
E4 0.9839 0.7824 0.9702 0.9883 0.66 
E5 0.9336 0.8534 0.9941 0.9861 0.50 
E6 0.9752 0.8672 0.9740 0.9804 0.61 
E7 0.9810 0.7730 0.9657 0.9783 0.62 
E8 0.9699 0.8241 0.9770 0.9880 0.62 
E9 0.9353 0.9405 0.9765 0.9396 0.48 
E10 0.9796 0.8488 0.9453 0.9443 0.64 
E11 0.9758 0.7703 0.9628 0.9560 0.58 
E12 0.9856 0.9093 0.9672 0.9872 0.67 
 
 
Fig. 6: ATR Spectrum of eprosartan and along with excipients, *A = Pure eprosartan, B = combination of eprosartan along with excipients 
 
 
Fig. 7: DSC Thermogram of Eprosartan and along with excipients, *A = Pure Eprosartan, B = combination of Eprosartan along with excipients 
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Attenuated total reflectance studies 
ATR spectrums of Pure Eprosartan mesylate and the final 
formulation are shown in fig. 6. From these graphs, it is clear that 
there are no interactions between the excipients and the drug, as 
there are no variations in the spectra. 
Differential scanning calorimetry 
DSC scans of pure drug Eprosartan as in fig. 7, indicated the melting 
point at 249.2 °C and the final formulation also shows the 
characteristic peak at 250.2 °C showing no major shift in peaks 
indicating the compatibility of the polymers. 
CONCLUSION 
Nanosuspension of Eprosartan mesylate was successfully prepared 
by using the precipitation method. Among all the formulations, E12 
prepared with Eudragit RL100 at 2.0% concentration showed a 
better release pattern and satisfactory zeta potential and particle 
size. The prepared formulations showed satisfactory dissolution and 
other evaluation characteristics. Hence the Eprosartan mesylate 
nanosuspension can be conveniently administered as an oral drug 
delivery system. 
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